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Abstract
A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine
against Plasmodium falciparum malaria. The present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a
target antigen in vaccine formulations against malaria caused by P. vivax. Recombinant proteins representing MSP-3a and
MSP-3b of P. vivax were expressed as soluble histidine-tagged bacterial fusions. Antigenicity during natural infection was
evaluated by detecting specific antibodies using sera from individuals living in endemic areas of Brazil. A large proportion of
infected individuals presented IgG antibodies to PvMSP-3a (68.2%) and at least 1 recombinant protein representing PvMSP-
3b (79.1%). In spite of the large responder frequency, reactivity to both antigens was significantly lower than was observed
for the immunodominant epitope present on the 19-kDa C-terminal region of PvMSP-1. Immunogenicity of the
recombinant proteins was studied in mice in the absence or presence of different adjuvant formulations. PvMSP-3b, but not
PvMSP-3a, induced a TLR4-independent humoral immune response in the absence of any adjuvant formulation. The
immunogenicity of the recombinant antigens were also tested in formulations containing different adjuvants (Alum,
Salmonella enterica flagellin, CpG, Quil A,TiterMaxH and incomplete Freunds adjuvant) and combinations of two adjuvants
(Alum plus flagellin, and CpG plus flagellin). Recombinant PvMSP-3a and PvMSP-3b elicited higher antibody titers capable of
recognizing P. vivax-infected erythrocytes harvested from malaria patients. Our results confirm that P. vivax MSP-3 antigens
are immunogenic during natural infection, and the corresponding recombinant proteins may be useful in elucidating their
vaccine potential.
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Introduction
Recent studies have made important advances toward the
development of a vaccine against human malaria caused by
Plasmodium falciparum. Clinical trials performed in African endemic
areas demonstrated 3 distinct antigens have a significant, albeit
partial, effect in retarding clinical malaria acquisition in vaccinated
children. These antigens are the circumsporozoite protein (CSP),
apical membrane antigen-1 (AMA-1), and merozoite surface
protein (MSP)-3 [1–3]. These results confirm the feasibility of an
effective malaria vaccine.
In contrast to P. falciparum malaria, vaccine development against
P. vivax malaria lags far behind. Few phase I clinical trials have
been performed and phase II trials have yet to be initiated [4–6].
This is a significant hurdle for malaria eradication, as a vaccine
against P. vivax is an essential step toward this objective [7].
To reduce the gap in the development of a vaccine against P.
vivax malaria, we and others have worked for the past 15 years,
characterizing naturally acquired immune responses to pre-
erythrocytic and blood-stage recombinant antigens in individuals
from endemic areas of South America [8–20]. A number of pre-
clinical studies in mice and non-human primates were performed
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using these recombinant antigens. These pre-clinical studies used
recombinant or synthetic antigens based on the CSP, MSP-1,
AMA-1, and Duffy-binding protein [21–27].
PfMSP-3.1 provided protective immunity in African children
vaccinated against P. falciparum infection [3], providing important
evidence that a comparable antigen from P. vivax may also be a
viable candidate for the development of a vaccine against vivax
malaria. In P. vivax, MSP-3 (PvMSP-3) comprises a family of
proteins characterized by a putative signal peptide, a central
alanine-rich domain, and the lack of a C-terminal transmembrane
domain or GPI anchor motif [28–30]. PvMSP-3a and PvMSP-3b
were initially predicted to form a-helical secondary and coiled-coil
tertiary structures with heptad repeats [28,29]. We recently
demonstrated that recombinant proteins based on predicted
coiled-coil domains of PvMSP-3a form oligomeric and elongated
molecules [31], suggesting this protein may mediate interactions
with host proteins or other merozoite surface proteins.
Based on the promising results of vaccination with P. falciparum
MSP-3.1 (the one member of the PfMSP3 family that has a central
domain of predicted coiled-coil structure [32]), this study was
designed to evaluate the antigenicity of four prokaryotic recom-
binant proteins representing PvMSP-3a or PvMSP-3b of P. vivax
in humans and mice.
Materials and Methods
Ethics Statement
Blood samples were obtained for research use with the written
informed consent of all study participants enrolled in a protocol
approved by the Ethics Committee of the Faculty of Pharmaceu-
tical Sciences of University of Sa˜o Paulo, Brazil (CEP No. 22/
2001), the Ethics Committee of the Faculty of Tropical Medicine,
Mahidol University, Thailand (MUTM 2010-006-01), and the
University of Oxford, Centre for Clinical Vaccinology and
Tropical Medicine, United Kingdom (OXTREC 027-025). This
study was performed in strict accordance with the recommenda-
tions in the Guide for the Care and Use of Laboratory Animals of
the Brazilian National Council of Animal Experimentation
(http://www.cobea.org.br/). The protocol was approved by the
Committee on the Ethics of Animal Experiments of the Faculty of
Pharmaceutical Sciences of University of Sa˜o Paulo, Brazil (CEEA
No. 112/2006).
Subjects
Serum samples were collected from 220 individuals with patent
P. vivax malaria in five different localities of the Amazon Region
and described in detail elsewhere [9,11]. These samples were
tested for the presence of IgG antibodies against the C-terminal
region of MSP-1 (PvMSP119), apical membrane antigen-1 (AMA-
1), and the Duffy binding protein (PvRII) [11,13,16]. A second
group was composed of 26 healthy adult volunteers selected from
blood donors in the city of Sa˜o Paulo, State of Sa˜o Paulo,
southeastern Brazil (control group).
Recombinant Proteins
The recombinant proteins presented in Table 1 were expressed
in Escherichia coli as described elsewhere [21,31]. Briefly, E. coli
BL21-DE3 (Novagen) containing the recombinant plasmids
pHISa-MSP-3a, pHISa-MSP-3b (FP-1), pHISb-MSP-3b (FP-2),
pET14b-MSP-3b (FP-3), and pET14b-MSP119 were cultivated in
1 L of LB-ampicillin (100 mg/mL) at 37uC shaken culture to
OD600 0.6–0.8. Recombinant protein expression was induced by
3 h incubation with 0.1 mM isopropyl-b-d thiogalactopyranoside
(IPTG, Life Technologies). The bacterial supernatant was
obtained by centrifugation at 24,000 g for 60 min at 4uC and
recombinant proteins were purified by affinity chromatography on
Ni2+-NTA Agarose (Qiagen) following by AKTA Prime using
anionic-columns (GE Healthcare). Fractions were analyzed by
SDS-PAGE and stained with Coomassie blue. Fractions contain-
ing recombinant proteins with a high degree of purity were pooled
and extensively dialyzed against PBS. The protein concentration
was determined spectrophotometrically at 280 nm. All batches of
recombinant proteins were tested by circular dichroism spectros-
copy, as described previously [31].
Adjuvants and Mouse Immunization
Initially, 4 groups of C57BL/6 (H-2b) and C57BL/6 TLR4
knockout (TLR4 KO, non-responsive to LPS) mice were
immunized subcutaneously (s.c.) with 10 mg of each recombinant
PvMSP-3 in the absence of adjuvants. Animals of 6–8 week-old
were purchased from Federal University of Sa˜o Paulo, Brazil. A
volume of 50 mL was injected into each footpad. After 15 and 30
days, each animal received a booster injection of 10 mg of the same
protein injected s.c. at the base of the tail.
PvMSP-3a and PvMSP-3b (FP-3) were selected for immuniza-
tion of BALB/c (H-2d) mice. The animals were purchased from
University of Sa˜o Paulo, Brazil. The immunization schedule was
the same as for C57BL/6 mice, except that the animals were
immunized in the presence of 6 adjuvants. In order, the antigens
included 25 mg of ImjectH Alum (Pierce), 2.5 mg of FliC flagellin of
Salmonella enterica Typhimurium, 10 mg of CpG-ODN 1826
(TCCATGACGTTCCTGACGTT) (Prodimol Biotecnologia),
25 mg of Quil A (Superfos Biosector), or an equal volume of
TiterMax Gold (Sigma) or Incomplete Freund’s Adjuvant (IFA).
PvMSP-3b (FP-3) was also co-administered in CPG ODN 1826
plus Alum or FliC. These adjuvants were administered at the doses
used for immunization with single adjuvants. Controls received
only PBS emulsified in adjuvant. Serum samples were collected for
analysis 14 days after each dose and stored at -20uC.
Immunological Assays
ELISA detection of human IgG antibodies. Human IgG
antibodies against PvMSP-3a, PvMSP-3b (FP-1, FP-2, and FP-3),
and PvMSP119 of P. vivax were detected by ELISA [11]. ELISA
plates were coated with 200 ng/well of each recombinant protein.
Fifty microliters of each solution were added to each well of a 96-
well plate (High binding, Costar). After overnight incubation at
room temperature (r.t.), the plates were washed with PBS-Tween
(0.05%, v/v) and blocked with PBS-milk (PBS, pH 7.4, containing
5% nonfat dry milk) for 2 h at 37uC. Serum samples were diluted
1:100 in the same solution and 50 mL of each sample was added to
duplicate wells. After incubation for 2 h at r.t. and washes with
PBS-Tween, 50 mL of a solution containing peroxidase-conjugated
goat anti-human IgG (Fc-specific) diluted 1:5.000 (Sigma) was
added to each well. The enzymatic reaction was developed by the
addition of 1 mg/mL o-p-phenylenediamine (Sigma) diluted in
phosphate-citrate buffer, pH 5.0, containing 0.03% (v/v) hydro-
gen peroxide, and stopped by the addition of 50 mL of 4 N H2SO4.
Plates were read at 492 nm (OD492) with an ELISA reader
(Awareness Technology, mod. Stat Fax 2100, EUA). Cutoff points
were set at 3 standard deviations above the mean OD492 of sera
from 26 individuals, unexposed to malaria, from the city of Sa˜o
Paulo. The results are expressed as index of reactivity (IR).
ELISA detection of mouse antibodies. Antibodies to
PvMSP-3 in mouse sera were detected by ELISA on days 14,
29, and 44 as described previously [33]. ELISA plates (High
binding, Costar) were coated with 200 ng/well of the homologous
recombinant protein. Each solution (50 mL) was added to each
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well of a 96-well plate. After overnight incubation at r.t., the plates
were washed with PBS-Tween and blocked with PBS-milk-BSA
(PBS, pH 7.4, containing 5% nonfat dry milk, 2.5% BSA) for 2 h
at 37uC. Mouse sera were tested in serial dilutions starting at
1:100; a final volume of 50 mL of sample was added to duplicate
wells, following incubation for 1 h at r.t. After washes with PBS-
Tween, 50 mL of a solution containing secondary antibody
conjugated to peroxidase (goat anti-mouse IgG, KPL) diluted
1:3.000 was added. The enzymatic reaction was developed as
described for ELISA detection of human IgG antibodies.
Detection of IgG subclass responses was performed as described
above, except the secondary antibody was specific to mouse IgG1,
IgG2a, IgG2b or IgG3 (Southern Technologies) diluted 1:8.000.
The specific anti-PvMSP-3 titers were determined as the highest
dilution yielding an OD492 greater than 0.1. The results are
expressed as means of IgG titers (Log10) 6 SEM.
P. vivax slide preparation and immunofluorescence
assays. The thin smears used for the IFA were prepared from
ex vivo matured and 45% percoll concentrated schizonts [34] that
were diluted 1:4 with uninfected RBCs to provide enough volume
to make a number of duplicate slides. Clinical isolates of P. vivax-
infected blood from malaria patients were collected at Shoklo
Malaria Research Unit (Thailand) with written informed consent.
Pooled sera from mice immunized 3 times with the recombinant
PvMSP-3a and PvMSP-3b (FP-3) proteins emulsified in Freund’s
Adjuvant (1:100) were applied to the smear and incubated for 1 h
before incubation with secondary anti-mouse IgG antibody
conjugated to Alexa Fluor 568 (Invitrogen) or DAPI (49,6-
diamidino-2-phenylindole, dihydrochloride, Invitrogen). The pres-
ence of native PvMSP-3 was visualized using a Nikon TS100
epifluorescence microscope.
Statistical Analysis
Differences between the proportions of responder individuals
were analyzed by the Chi-square test. Comparison of antibody
level (IR) in independent samples was performed by One-way
analysis of variance (ANOVA) and correlations were determined
by the nonparametric Spearman correlation coefficient. One-way
ANOVA was used to compare normally distributed log-trans-
formed means for the different animal groups. Multiple compar-
isons were assessed by Tukey’s Test, with a P-value of ,0.05
considered significant.
Results
Antigenicity of Recombinant PvMSP-3a or PvMSP-3b
Proteins
Initially, we compared the IgG antibody response of individuals
during patent infection to the recombinant PvcMSP-3a and
PvMSP-3b (FP-1, FP-2, and FP-3) Proteins. Details of each
recombinant protein can be found in our previously published
studies on the biochemistry of these proteins [31]. The frequency
of responders to MSP-3a and at least one recombinant protein
representing PvMSP-3b was 68.2% and 79.1%, respectively,
indicating both proteins are immunogenic during infection with P.
vivax. The frequency of individuals presenting IgG antibodies to
each recombinant PvMSP-3b was 26.3% (FP-1), 64.5% (FP-2),
and 65.9% (FP-3). The prevalence of antibodies against FP-1 was
significantly lower than the prevalence of antibodies against FP-2
and FP-3 of PvMSP-3b (Chi-square test, p,0.001). Reactivity to
FP-2 and FP-3 of PvMSP-3b did not statistically differ (p.0.05).
We also compared the reactivity of each PvMSP-3 recombinant
protein with an immunodominant epitope of P. vivax, contained
within the PvMSP119 protein [9,11]. The responder frequency
and reactivity index in malaria-infected individuals with
PvMSP119 were significantly higher when compared to the other
recombinant proteins (p,0.001, Figure 1A and B, respectively).
After repeated exposure, differences in reactivity between
PvMSP119 and the recombinant PvMSP-3 proteins were main-
tained (p,0.0001 to PvMSP-3a and PvMSP-3b FP-1, p,0.01 to
PvMSP-3b FP-2, and p,0.001 to PvMSP-3b FP-3, Figure 1C).
The proportions of responders to FP-2 and FP-3 increased
significantly after repeated P. vivax infection reaching more than
80% in multiply infected individuals, indicating most individuals
may become responders based on their degree of exposure. Such a
pattern was not observed in response to FP-1 (Figure 1C).
We also evaluated the correlation between antibody reactivities
to paired recombinant proteins during patent infection. In all
cases, significant correlations were observed. For example, there
was a relatively high correlation between PvMSP-3a and PvMSP-
3b FP-2 (r = 0.56, p,0.0001; Figure 2B), or PvMSP-3b FP-2 and
PvMSP-3b FP-3 (r = 0.59, p,0.0001; Figure 2F), and a moderate
correlation between PvMSP-3a and PvMSP-3b FP-3 (r = 0.41,
p,0.0001; Figure 2C) or PvMSP-3b FP-1 and PvMSP-3b FP-2
(r = 0.33, p,0.0001; Figure 2D), or PvMSP-3b FP-1 and FP-3
(r = 0.42, p,0.0001; Figure 2E). Overall, the correlations between
the antibody reactivities to PvMSP119 and the other recombinant
proteins (Figures 2G, 2H, 2I, and 2J) were weak.
Immunogenicity of Recombinant PvMSP-3a and PvMSP-
3b Proteins in Mice
The immunogenicity of recombinant proteins representing
PvMSP-3a and PvMSP-3b was evaluated after immunization of
C57BL/6 wild type (WT) mice. Animals immunized with PvMSP-
3a failed to respond even after three immunizing doses (Figure 3A).
In contrast, we detected specific antibodies in mice immunized 2
or 3 times with any of the PvMSP-3b proteins (Figures 3B, 3C,
3D). The antibody titers to PvMSP-3b FP-2 were higher than the
titers to PvMSP-3b FP-1 or FP3 (p,0.01). In addition, the titers to
Table 1. Recombinant proteins used in the immunological studies.
Protein Fragment Name Sequence Expression vector Apparent molecular weights
PvMSP-3a FP-1 359–798 pHISa 87 kDa
PvMSP-3b FP-1 35–375 pHISa 60 kDa
PvMSP-3b FP-2 385–654 pHISb 57 kDa
PvMSP-3b FP-3 35–654 pET14b 104 kDa
PvMSP-1 MSP119 1616–1704 pET14b 18 kDa
FP = Fusion Protein with His-tag.
doi:10.1371/journal.pone.0056061.t001
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PvMSP-3b FP-1 were higher than the titers to FP-3 (p,0.01,
Figures 3B, 3C, and 3D).
Because bacterial recombinant proteins are often contaminated
with LPS, we also compared the WT response to that of LPS-
unresponsive TLR4 KO mice.
Similar titers were detected in WT and TLR4 KO mice
following immunization with PvMSP-3b FP-1 and FP-3
(Figures 3B and 3D). In the case of PvMSP-3b FP-2, the titers
of WT mice were significantly higher than in the TLR4 KO mice
(p,0.05), suggesting a possible effect of LPS contamination in the
protein preparation (Figure 3C). Nevertheless, specific antibodies
are still observed after PvMSP-3b FP-2 immunization.
Adjuvant and Antibody Responses after Immunization
with PvMSP-3a and PvMSP-3b (FP-3)
High antibody titers are desirable for vaccine efficacy. Toward
that goal, we attempted to identify adjuvants that could
significantly improve specific antibody responses. Our main goal
was to obtain, if possible, titers similar to those elicited by
immunization in the presence of Freund’s adjuvant. To test
different adjuvant formulations, we selected 2 recombinant
proteins, PvMSP-3a and full-length PvMSP-3b (FP-3). We used
adjuvant formulations containing Alum, Quil A, TiterMax, IFA,
and the TLR-5 or -9 agonists (FliC or CPG ODN 1826,
respectively). Both recombinant proteins were highly immuno-
genic in BALB/c mice when administered in the presence of
adjuvant (Figures 4 and 5). At the end of the immunization
schedule, mice immunized with PvMSP-3a in Quil A, TiterMax,
or IFA had significantly higher antibody titers than mice
immunized with other adjuvant formulations (Figure 4C,
p,0.001 in all cases). No statistically significant differences in
antibody titers were detected in mice immunized with PvMSP-3a
in Quil A, TiterMax, or IFA (p.0.05). However, mice immunized
with PvMSP-3a formulated in CPG-ODN 1826 also had high
antibody titers in comparison to FliC (p,0.05) or Alum (p,0.001).
The mean antibody titers obtained with FliC and Alum did not
significantly differ (p.0.05). Control mice immunized with
adjuvants only did not present specific antibodies to PvMSP-3a
throughout the experiment. The only exception was FliC-
immunized mice, which had a low antibody immune response to
PvMSP-3b (Figure 5). In this experiment, we observed that after
the third dose, animals immunized with PvMSP-3b in CPG ODN
1826, Quil A, or TiterMax presented antibody titers similar to
those of mice immunized with antigen in IFA (P.0.05)
(Figure 5C). However, when administered with Alum or FliC
antibody, titers to PvMSP-3b were significantly lower (p,0.001).
FliC proved to be the most efficient adjuvant, generating antibody
titers significantly higher than Alum (p,0.05). Interestingly, when
CPG ODN 1826 was administered with Alum or FliC, it improved
their activity, producing antibody titers as high as the IFA-
immunized group (Figure 5C).
The Th bias of the immune response was analyzed by
determination of IgG subclasses in immunized by BALB/c mice.
As shown in Figure 6, high levels of IgG1 were observed in mice
immunized with Alum, in comparison to other groups, indicating
Th2 polarization (IgG1/IgG2a ratio: 112). However, co-admin-
istration of Alum with CPG ODN 1826 greatly reduced the IgG1/
IgG2a ratio in comparison to the adjuvant alone (Alum plus CPG
ODN 1826:112 vs. 0.36, p,0.05). Although co-administration of
Alum plus FliC also modulated the Th1/Th2 response in
Figure 1. Human antibody response to recombinant PvMSP-3a,
PvMSP-3b, and PvMSP119 proteins during patent P. vivax
infection. A) The bars express the percent response for each of the
analyzed proteins. Sera from 220 individuals were analyzed for the
presence of specific IgG antibodies by ELISA and tested at a 1:100
dilution in duplicate. The cutoff proteins obtained from the PvMSP-3a,
PvMSP-3b (FP-1), PvMSP-3b (FP-2), PvMSP-3b (FP-3), and PvMSP119 were
0.179, 0.715, 0.195, 0.396, and 0.185, respectively. B) Comparison of
individual IR IgG antibodies to MSPs in sera of individuals infected by P.
vivax. The line indicates the limit of positivity (IR = 1). IR: Index of
reactivity (mean absorbance of test serum/cutoff). C) Comparative
analysis of the IgG antibody response against MSP proteins and the
frequency of previous episodes of vivax malaria. We analyzed 213 serum
samples from individuals who reported the number of previous
episodes of malaria for the presence of specific IgG antibodies by
ELISA. All sera were tested in duplicate at 1:100 dilution. *: the
percentage of responders with statistically significant correlation to the
frequency of previous malaria episodes.
doi:10.1371/journal.pone.0056061.g001
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comparison to FliC alone, this difference was not statistically
significant (IgG1/IgG2a ratio: 22 vs. 1.63, p.0.05). A more
balanced Th1/Th2 response was observed in mice immunized
with PvMSP-3b in FliC, CPG-ODN 1826, Quil A, TiterMax, and
IFA (IgG1/IgG2a ratio between 0.35 and 28).
In addition to IgG1 and IgG2a, in many cases, we have also
detected the presence of IgG2b and IgG3. The results are
summarized on Figure S1.
Recognition of Native Protein in P. Vivax Parasites
Pooled sera from mice immunized three times with PvMSP-3a
and PvMSP-3b in Freund’s Adjuvant were tested for their ability
to recognize native protein expressed by P. vivax merozoites. Both
sera reacted with native protein exposed on the surface of P. vivax
parasites isolated from an infected individual, but not with control
sera. The IFA patterns obtained with these sera are shown in
Figure 7, where the schizonts appeared as a ‘‘bunch of grapes’’
Figure 2. Reactivity against recombinant PvMSP-3 and PvMSP119 proteins in 220 sera from individuals with patent P. vivax malaria
infection. Each panel represents the reactivity index of serum samples against the indicated recombinant proteins. The serum samples were tested
at a 1:100 dilution, as described in Figure 1B. Symbols represent the IR IgG antibodies against recombinant MSP proteins in the sera of P. vivax-
infected individuals. The values of the Spearman correlation coefficient (r) and p values are shown in each panel.
doi:10.1371/journal.pone.0056061.g002
Figure 3. IgG antibody response in C57BL/6 wild-type (WT) and TLR4 KO mice after immunization with MSP-3 in the absence of
adjuvant. Groups of 5 mice were immunized 3 times (s.c.) with 10 mg of PvMSP-3a, PvMSP-3b (FP-1), PvMSP-3b (FP-2), or PvMSP-3b (FP-3) and
antibody titers to homologous PvMSP-3 were determined after each dose. Results are expressed as the means of antibody titers (log10) 6 SEM and
were compared by one-way ANOVA followed by Tukey’s test for multiple comparisons. After the third dose, non-significant differences between
groups of immunized mice (C57BL/6 WT vs. TKR4 KO) are denoted on the graph as ‘‘n.s.’’ Significant difference between 2 groups of mice immunized
with 3 doses of PvMSP-3b (FP-2) are denoted on the graph (*p,0.05).
doi:10.1371/journal.pone.0056061.g003
Immunological Properties of P. vivax MSP-3
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Figure 4. IgG anti-PvMSP-3a in mice immunized with various
adjuvant formulations. Groups of 6 female BALB/c mice were
immunized 3 times (s.c.) with 10 mg of protein in the following adjuvant
formulations: Alum, FliC, CpG ODN 1826, Quil A, TiterMax, or IFA. Anti-
PvMSP-3a in the sera of immunized mice was analyzed by ELISA 2
weeks after the first (A), second (B), and third (C) immunizing dose.
Results are expressed as mean IgG antibody titers (log10) 6 SEM and
were compared by one-way ANOVA followed by Tukey’s test for
multiple comparisons. Significant differences are noted on the graph:
*p,0.05; **p,0.01; ***p,0.001. Non-significant (n.s.) differences are
indicated (p.0.05). Data representative of 2 independent experiments.
doi:10.1371/journal.pone.0056061.g004
Figure 5. IgG anti-PvMSP-3b and IgG subclass profiles in mice
immunized in the presence of adjuvant. Groups of 6 females
BALB/c were immunized 3 times (s.c.) with 10 mg of protein in the
presence of the following adjuvant formulations: Alum, FliC, CpG ODN
1826, Quil A, TiterMax, or IFA. The adjuvants Alum, FliC, and CpG ODN
1826 were also tested in combination (Alum plus CpG ODN 1826 and
FliC+CpG ODN 1826). Anti-PvMSP-3b in the sera of immunized mice was
analyzed by ELISA 2 weeks after the first (A), second (B), and third (C)
doses. Results are expressed as mean IgG antibody titers (log10) 6 SEM
and were compared by one-way ANOVA followed by Tukey’s test for
Immunological Properties of P. vivax MSP-3
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when stained [28]. It is important to note that some schizonts
stain, but others do not. This fact could be explained by the
presence in infected of patients of multiple clones of P. vivax
parasites expressing multiple alleles of PvMSP-3a and PvMSP-3b.
Discussion
We evaluated the immunogenic properties of four recombinant
proteins representing MSP-3a and MSP-3b of P. vivax; one
representing the C-terminal region of PvMSP-3a and three
representing different regions of PvMSP-3b. Initially, these
recombinant proteins were compared for their ability to bind
IgG antibodies in the serum of individuals exposed to P. vivax
malaria. We demonstrated that the frequencies of individuals with
IgG antibodies to PvMSP-3a and at least one of the three
recombinant proteins representing PvMSP-3b were relatively high
(68.2% and 79.1%, respectively). For PvMSP-3a, these findings
confirm two recent studies performed in distinct endemic areas of
the Brazilian Amazon, where 78% [19] and 58.4% [20] of
individuals presented IgG antibodies to this protein.
Previous studies evaluated the polymorphism in the C-terminal
region of PvMSP-3a and found the region is highly conserved
among natural isolates [35]. This fact may account for the
recognition by IgG antibodies from a relatively high percentage of
individuals. In contrast to the C-terminal region of PvMSP-3a, a
variable degree of polymorphism has been reported for the gene
encoding PvMSP-3b [36]. Despite the reported sequence diversity
of PvMSP-3b, we found a significant percentage of individuals
recognized PvMSP-3b recombinant proteins FP-2 and FP-3
(.60.0%). Nevertheless, we detected a lower frequency (26.3%)
of responders to PvMSP-3b recombinant protein FP-1, suggesting
most of the antibody responses were directed to the second moiety
of the protein. The PvMSP-3a and PvMSP-3b polymorphic
frequency in the studied areas is unknown. A recent study used
PCR-RFLP to characterize the diversity of MSP-3a in 60 P. vivax
isolates from four geographic regions of the Brazilian Amazon.
The results revealed a high diversity where three different
fragment sizes were found [37].
The cause for differential recognition by human antibodies of
the N- and C-terminal regions of PvMSP-3b (FP-2 and FP-3) does
not seem to be related to the absence of proper folding. In a
previous study involving circular dichroism experiments, we
demonstrated FP-1 was better structured than FP-2, which was
highly recognized by IgG antibodies [31].
The comparison of human antibody reactivities to different
antigens revealed major correlations. Significant correlations were
observed between FP-2 and FP-3 of PvMSP-3b, possibly because
they share a number of common B and T cell epitopes. However,
the lack of correlation in most cases reflects differential genetic
control by human HLA molecules. This hypothesis is being tested.
To investigate the immunogenic properties of PvMSP-3a and
PvMSP-3b as vaccine candidates, we tested their immunogenicity
in the presence or absence of different adjuvant systems in pre-
clinical vaccinations of mice. In the absence of adjuvant, some of
PvMSP-3b recombinant proteins elicited a specific TLR4-inde-
pendent antibody response. This observation may explain how
these molecules are immunogenic during natural human infection.
In contrast, PvMSP-3a did not induce antibody immune
responses, indicating the presence of other molecules in the
parasite providing the adjuvant signal.
multiple comparisons. Significant differences are noted on the graph:
*p,0.05; **p,0.01; ***p,0.001. Non-significant (n.s.) differences are
indicated (p.0.05). Data representative of 2 independent experiments.
doi:10.1371/journal.pone.0056061.g005
Figure 6. Serum IgG isotype responses in mice after immunization with PvMSP-3b in the presence of adjuvant. BALB/c mice were
immunized with recombinant PvMSP-3b in the presence of adjuvant as described in Figure 5. PvMSP-3b-specific IgG1 and IgG2a antibody titers in the
sera of immunized mice were analyzed by ELISA 2 weeks after the third dose. Results are the means of IgG1/IgG2a 6 SEM for 6 mice per group. All
groups were compared by one-way ANOVA and Tukey’s test for multiple comparisons.
doi:10.1371/journal.pone.0056061.g006
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Previous studies have demonstrated that a major challenge in
the development of subunit vaccines for malaria is the identifica-
tion of a safe and potent adjuvant capable of inducing immune
responses high antibody titers [38]. Antibody titers were very high
in animals vaccinated with the C-terminus of PvMSP-3a or
different regions of PvMSP-3b emulsified in IFA; thus, these
recombinant proteins can be highly immunogenic. Our results
indicate PvMSP-3a or a protein representing the majority of the
PvMSP-3b sequence (FP-3) were immunogenic when adminis-
tered in adjuvants other than IFA. The immunogenicity of
PvMSP-3a was greater when administered in Quil A, a saponin
derived from the bark of a Chilean tree, Quillaja saponaria, than in
Alum, FliC, or CpG ODN 1826 and was similar to IFA. In
addition, the antigen in TiterMax generated antibody titers similar
to that obtained in IFA. PvMSP-3b yielded high antibody titers in
all tested adjuvants, although Alum and FliC failed to perform at
the level of IFA; however, TLR-9 agonist CPG ODN 1826
improved their adjuvant activity. It is of interest to note that
adjuvants such as Alum, FliC, TiterMax, and IFA tend to induce
Th2 with high IgG1/IgG2a ratios, whereas CPG ODN 1826 and
Quil A show a clear modulation of the IgG subclass response
pattern to a more balanced Th1/Th2 response.
The cellular response to CpG DNA is mediated by TLR9,
followed by induction of pro-inflammatory cytokines (e.g. IL-12,
TNF-a, and IFN-c), and producing a strong Th1 response [39].
We observed a response pattern favoring Th1 in all formulations
containing CPG ODN (CPG ODN 1826 alone, Alum+CPG
ODN 1826, and FliC+CPG ODN 1826). Clinical trials evaluating
the adjuvant activity of CpG ODN with vaccines designed to
prevent malaria have been reported [40–43]. Co-administration of
CpG with AMA-1 [40] or MSP142 of P. falciparum [43] increased
the geometric media of antibodies by 5.5 or 8-fold, respectively,
when compared to each protein alone.
The relevance of antibodies against PvMSP-3a or b in host
protection remains untested. Evidence in favor of a protective role
for anti-P. vivax MSP-3 was obtained by clinical trials performed
with P. falciparum MSP3.1 [3]. The functional role(s) for the
parasite and in the context of host immune responses remain to be
determined for other members of the MSP3 family in each of these
species [32]. Such investigations as a whole should help guide
decisions for the development of malaria vaccines based on these
or alternative proteins, which could prove to be valuable in areas
of the world afflicted with both P. falciparum and P. vivax.
Supporting Information
Figure S1 Serum IgG isotype responses in mice after
immunization with PvMSP-3 in the presence of adju-
vant. BALB/c mice were immunized with the recombinant
proteins PvMSP-3a (A) or PvMSP-3b FP-3 (B) in the presence of
adjuvant as described in Figures 4 and 5. IgG1, IgG2a, IgG2b and
IgG3 antibody titers in the sera of immunized mice were analyzed
by ELISA 2 weeks after the third dose. Results are expressed as
mean IgG antibody titers (log10) 6 SEM for 6 mice per group.
(TIF)
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